Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments
| Autor: | Max M. van Noesel, Nelleke Tolboom, Sylvia T M Wenker, Marnix G.E.H. Lam, Atia Samim, Bart de Keizer, Kristell L S Chatalic, Gitta Bleeker, Godelieve A.M. Tytgat, Alex J. Poot |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Poor prognosis [68Ga]Ga-DOTA peptides lcsh:Medicine Medicine (miscellaneous) Review Malignancy Scintigraphy 030218 nuclear medicine & medical imaging 03 medical and health sciences neuroblastoma 0302 clinical medicine Nuclear medicine imaging Neuroblastoma [123I]mIBG medicine Recurrent disease [124I]mIBG nuclear medicine radionuclide imaging [18F]F-DOPA medicine.diagnostic_test [18F]mFBG business.industry lcsh:R medicine.disease [11C]mHED Positron emission tomography 030220 oncology & carcinogenesis Radiology [18F]FDG business Emission computed tomography |
| Zdroj: | Journal of Personalized Medicine Journal of Personalized Medicine, Vol 11, Iss 270, p 270 (2021) |
| ISSN: | 2075-4426 |
| Popis: | Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis, approximately 50% of patients present with metastatic disease. These patients are at high risk for refractory or recurrent disease, which conveys a very poor prognosis. During the past decades, nuclear medicine has been essential for the staging and response assessment of neuroblastoma. Currently, the standard nuclear imaging technique is meta-[123I]iodobenzylguanidine ([123I]mIBG) whole-body scintigraphy, usually combined with single-photon emission computed tomography with computed tomography (SPECT-CT). Nevertheless, 10% of neuroblastomas are mIBG non-avid and [123I]mIBG imaging has relatively low spatial resolution, resulting in limited sensitivity for smaller lesions. More accurate methods to assess full disease extent are needed in order to optimize treatment strategies. Advances in nuclear medicine have led to the introduction of radiotracers compatible for positron emission tomography (PET) imaging in neuroblastoma, such as [124I]mIBG, [18F]mFBG, [18F]FDG, [68Ga]Ga-DOTA peptides, [18F]F-DOPA, and [11C]mHED. PET has multiple advantages over SPECT, including a superior resolution and whole-body tomographic range. This article reviews the use, characteristics, diagnostic accuracy, advantages, and limitations of current and new tracers for nuclear medicine imaging in neuroblastoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|